# The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

> **NCT00154323** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 55 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Oxcarbazepine

## Key facts

- **NCT ID:** NCT00154323
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154323, "The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00154323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*